Heart Failure News and Research

RSS
Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.
HeartWare International gets approval to market HeartWare Ventricular Assist System in Canada

HeartWare International gets approval to market HeartWare Ventricular Assist System in Canada

Cedars-Sinai Heart Institute sets new national standard for most adult heart transplants

Cedars-Sinai Heart Institute sets new national standard for most adult heart transplants

Changes in height can affect risk of coronary heart disease

Changes in height can affect risk of coronary heart disease

Medication adherence interventions for heart failure patients

Medication adherence interventions for heart failure patients

Thoratec gets final FDA approval to expand enrollment of HeartMate III U.S. clinical trial

Thoratec gets final FDA approval to expand enrollment of HeartMate III U.S. clinical trial

Older mothers who exercise during pregnancy can reduce baby's risk of congenital heart defects

Older mothers who exercise during pregnancy can reduce baby's risk of congenital heart defects

Prolonged insulin therapy often unnecessary in children with Type 2 diabetes

Prolonged insulin therapy often unnecessary in children with Type 2 diabetes

Cardio3 BioSciences announces successful completion of futility analysis for C-Cure

Cardio3 BioSciences announces successful completion of futility analysis for C-Cure

New Johns Hopkins mobile app educates care providers on improving sleep, overall health of patients

New Johns Hopkins mobile app educates care providers on improving sleep, overall health of patients

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Penn surgeons develop new tools to identify joint replacement patients at risk for serious complications

Penn surgeons develop new tools to identify joint replacement patients at risk for serious complications

Veterans with PTSD at higher risk of developing heart failure

Veterans with PTSD at higher risk of developing heart failure

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Novasep, Celladon sign agreement to develop and supply MYDICAR drug substance

Qualcomm Life, AMC Health to accelerate transformation of health care delivery for at-risk patients

Qualcomm Life, AMC Health to accelerate transformation of health care delivery for at-risk patients

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

Mast plans to develop vepoloxamer for chronic heart failure treatment

Mast plans to develop vepoloxamer for chronic heart failure treatment

Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.